COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: Preliminary investigation

Journal of Clinical Psychopharmacology

Volumn 32, Issue 1, 2012, Pages 135-137

  Heinzerling, Keith G ^a   McCracken, James T ^a   Swanson, Aimee Noelle ^a   Ray, Lara A ^b   Shoptaw, Steven J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; METHAMPHETAMINE; MODAFINIL; MU OPIATE RECEPTOR; NALTREXONE;

ADULT; ALCOHOLISM; CAUCASIAN; COGNITION; COGNITIVE THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC MARKER; GENOTYPE; HETEROZYGOTE; HISPANIC; HUMAN; LETTER; MAJOR CLINICAL STUDY; METHAMPHETAMINE DEPENDENCE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ALLELES; AMPHETAMINE-RELATED DISORDERS; BEHAVIOR THERAPY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITIVE THERAPY; FEMALE; GENOTYPE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855385154     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318240a48e     Document Type: Letter

References (8)

1. Heinzerling KG, Swanson AN, Kim S, et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010;109(1-3):20-29.
2. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257-269. (Pubitemid 36144114)
3. Flanagin BA, Cook EH Jr de Wit H. An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(6):576-583. (Pubitemid 44434657)
4. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O- methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243-250. (Pubitemid 26226317)
5. Hamidovic A, Dlugos A, Palmer AA, et al. Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr Genet. 2010;20(3):85-92.
6. Mague SD, Blendy JA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend. 2010;108(3):172-182.
7. Dlugos AM, Hamidovic A, Hodgkinson C, et al. OPRM1 gene variants modulate amphetamine-induced euphoria in humans. Genes Brain Behav. 2011;10(2):199-209.
8. Bodenmann S, Xu S, Luhmann UFO, et al. Pharmacogenetics of modafinil after sleep loss: catechol-O-methyltransferase genotype modulates waking functions but not recovery sleep. Clin Pharmacol Ther. 2009;85(3):296-304.